RECENT NEWS

Do you want to link to this Amgen Site and leave Amgen.co.kr?

YOU ARE NOW LEAVING AMGEN KOREA'S WEB SITE. Amgen Korea takes takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Amgen Korea Hosts the 4th Amgen Science Academy 2021: Patient Centricity Symposium

  • This large-scale online symposium is a venue to discuss meaning and realization of patient centricity with 280 medical professionals from both home and abroad
  • Amgen shares its know-how in development of new drugs driven by the corporate mission of To Serve Patients with patients’ real voice at the heart of every step from R&D to access to care improvements

(25 Oct. 2021) Amgen Korea (GM: Sang Noh), one of the leading biotechnology companies, announced on 25 Oct. the successful hosting of the 4th Amgen Science Academy 2021: Patient Centricity Symposium attended by 280 healthcare professionals from both home and abroad. The symposium was opened by the plenary session on 20 Oct and will be wrapped up with the therapeutic area (TA)-level breakout sessions on 23 and 30 Oct.

An event arranged by Amgen Medical since 2018, the Amgen Science Academy is an occasion to exchange thoughts and ideas about values and utility of Amgen’s expertise in science and medical approach that drive the development of transformative medicines, and this year marks its 4th anniversary. It previously served as a venue to have in-depth discussions about areas of life sciences where Amgen holds a leadership position like monoclonal antibody, genetics and real-world evidence (RWE); and this year’s theme is Patient Centricity to discuss down-to-earth values and practical activities that can bring patient centricity to life. This year, the symposium talks about initiatives at Amgen driven by its corporate mission of To Serve Patients, to realize its patient-centricity from R&D to approval and reimbursement.

On the first day, participants had a chance to understand what patient-centricity really means and discuss how to reach out to patients in a way that their medical unmet needs can be addressed. Dr. Victoria Elegant, Vice President and Region Head of Medical, Amgen APAC, opened the day by introducing the meaning and values of patient-centricity at Amgen; and it was followed by the presentation from Darshna Patel, Director, Regulatory Affairs, Amgen Global, who shared how real-voice from patients are reflected in development of new therapies. Director Patel explained that new drug development starts from identification of TAs with patients’ needs, and not just efficacy and safety profile observed in clinical trials but also patient-reported outcomes like quality of living should all be factored into. Thorough analysis of patients’ experience and pharmaceutical preferences through validated tools is important as they are all closely related to the entire cycle from approval and launch to promotion and reimbursement; and Amgen has been taking this approach and reflecting patients’ real voice, which has led to successful development of transformative therapies for diseases with no other treatment options, she emphasized. Colin Baughman, founder and Managing Partner of True North Solutions, medical affairs consulting firm in the U.S., then gave the presentation about how to gather patients’ opinion and cases of digital technologies being used in each TA; and Prof. Aaron Hansen, Princess Margaret Cancer Centre in Canada, also introduced clinical trials where patients’ voice was heard.

The sessions on 23 Oct. discussed the values and importance of medical communication driven by patient centricity in TAs Amgen Korea focuses on like bone diseases, cardiovascular (CV) diseases and oncology, and shared how patients’ voice can be reflected in different clinical trial phases and results. During the CV session, Dr. Schuyler Jones, Duke University Medical Center, talked about examples of clinical trials based on RWE and proposed potential approaches to realize patient-centricity in real world, inviting all participants to exchange ideas and thoughts freely. At the bone disease session, Prof. Dong-won Byun, Endocrinology and Metabolism, Soon Chun Hyang University Hospital Seoul, introduced local patient-centric clinical cases in osteoporosis, which was followed by a panel discussion with renowned professors from Korea about the current clinical landscape here at home. For the oncology session, Monica Batra, Director, Regulatory Affairs, Amgen Global, presented what a patient-centric clinical trial means for approval of new drug. At the breakout session on hematological types of cancer to be held on 30, Colin Baughman from True North Solutions will present cases of and results from Social Listening for patients with multiple myeloma; and Prof. Ju-hee Jo, Samsung Advanced Institute for Health Sciences & Technology, will give the presentation about interpretation and clinical implementation of patient-reported outcomes and quality of life in clinical trials as well as recent trends and landscape.

Dr. Victoria Elegant, Vice President and Region Head of Medical, Amgen APAC, said: “Accelerated advancements in the biopharmaceutical industry and technologies on top of improved access to information support patients to play a more active role in making treatment-related decisions for themselves. Amgen’s endeavor to improve access to its transformative biopharmaceuticals for more patients is well reflected in all strategic steps from R&D to approval and regulatory affairs. This year’s Amgen Korea Science Academy marks a very meaningful occasion to have an in-depth medical discussion with healthcare professionals from Korea about how to bring patient-centricity to life.”

Sang Noh, GM, Amgen Korea, said: “The Amgen Science Academy led by Amgen Korea has become one of the most representative programs where a comprehensive scientific discourse can be unfolded regarding medical science research as a whole that goes beyond certain TAs with this year particular focusing on patient centricity. Amgen has remained committed to research and development of innovative medicines in TAs with limited or no treatment options, and patients have always been at the heart of all decisions we make throughout that journey. As a biotechnology leader, we will never lose sight of our mission of To Serve Patients and continue to carefully listen to what patients have to say in areas with no treatment options.”

# # #

This media release was prepared to provide information on Amgen’s general business activities. Please take care not to risk potential violation of laws and regulations related to pharmaceutical advertising when referring to information contained in the media release.

About Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be the world’s largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit www.amgen.com.

About Amgen Korea

Amgen Korea was established in November 2015 to further develop Amgen’s clinical pipeline which offers a wide range of products for bone disease, cardiovascular, oncology/hematology, nephrology, inflammation, neuroscience treatment and biosimilars, as well as to provide innovative medicines to patients in Korea who are suffering from severe diseases. As a member of the biotechnical industry, Amgen Korea will continue to contribute to the development of the Korean pharmaceutical industry by carrying forward diversified and positive activities.

Forward-Looking Statements

This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation.

We perform a substantial amount of our commercial manufacturing activities at a few key facilities and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to acquire other companies or products and to integrate the operations of companies we have acquired may not be successful.

A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.

CONTACT:
Amgen Korea

Min-Jung Jung (mjung02@amgen.com)

Mikyung Shin (mshin@amgen.com)

# # #